Loading...

Cutera

Nasdaq:CUTR
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CUTR
Nasdaq
$351M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The last earnings update was 67 days ago. More info.


Add to Portfolio Compare Print
  • Cutera has significant price volatility in the past 3 months.
CUTR Share Price and Events
7 Day Returns
14.7%
NasdaqGS:CUTR
0.1%
US Medical Equipment
1.1%
US Market
1 Year Returns
-42.2%
NasdaqGS:CUTR
15.5%
US Medical Equipment
4.7%
US Market
CUTR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cutera (CUTR) 14.7% 39.8% 52.5% -42.2% 132.3% 151.5%
US Medical Equipment 0.1% 3.3% 9% 15.5% 62.4% 104%
US Market 1.1% 4.3% 2.9% 4.7% 37.7% 43.6%
1 Year Return vs Industry and Market
  • CUTR underperformed the Medical Equipment industry which returned 15.5% over the past year.
  • CUTR underperformed the Market in United States of America which returned 4.7% over the past year.
Price Volatility
CUTR
Industry
5yr Volatility vs Market

CUTR Value

 Is Cutera undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cutera to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cutera.

NasdaqGS:CUTR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:CUTR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.87
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.869 (1 + (1- 21%) (2.73%))
0.925
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.92
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.925 * 5.96%)
8.24%

Discounted Cash Flow Calculation for NasdaqGS:CUTR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cutera is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:CUTR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.24%)
2020 -0.27 Analyst x1 -0.24
2021 6.56 Analyst x1 5.60
2022 9.55 Est @ 45.52% 7.53
2023 12.67 Est @ 32.68% 9.23
2024 15.67 Est @ 23.69% 10.55
2025 18.40 Est @ 17.41% 11.44
2026 20.79 Est @ 13% 11.94
2027 22.85 Est @ 9.92% 12.13
2028 24.63 Est @ 7.76% 12.07
2029 26.17 Est @ 6.25% 11.85
Present value of next 10 years cash flows $92.09
NasdaqGS:CUTR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $26.17 × (1 + 2.73%) ÷ (8.24% – 2.73%)
$487.63
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $487.63 ÷ (1 + 8.24%)10
$220.85
NasdaqGS:CUTR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $92.09 + $220.85
$312.94
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $312.94 / 14.04
$22.29
NasdaqGS:CUTR Discount to Share Price
Calculation Result
Value per share (USD) From above. $22.29
Current discount Discount to share price of $25.02
= -1 x ($25.02 - $22.29) / $22.29
-12.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Cutera is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cutera's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cutera's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:CUTR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.66
NasdaqGS:CUTR Share Price ** NasdaqGS (2019-07-16) in USD $25.02
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 41.31x
United States of America Market PE Ratio Median Figure of 3,084 Publicly-Listed Companies 17.98x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cutera.

NasdaqGS:CUTR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CUTR Share Price ÷ EPS (both in USD)

= 25.02 ÷ -2.66

-9.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cutera is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Cutera is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Cutera's expected growth come at a high price?
Raw Data
NasdaqGS:CUTR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
80.1%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.32x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cutera, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cutera's assets?
Raw Data
NasdaqGS:CUTR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.79
NasdaqGS:CUTR Share Price * NasdaqGS (2019-07-16) in USD $25.02
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.3x
United States of America Market PB Ratio Median Figure of 5,240 Publicly-Listed Companies 1.81x
NasdaqGS:CUTR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CUTR Share Price ÷ Book Value per Share (both in USD)

= 25.02 ÷ 2.79

8.98x

* Primary Listing of Cutera.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cutera is overvalued based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Cutera's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Cutera has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CUTR Future Performance

 How is Cutera expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
80.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cutera expected to grow at an attractive rate?
  • Cutera's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Cutera's earnings growth is expected to exceed the United States of America market average.
  • Cutera's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:CUTR Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:CUTR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 80.1%
NasdaqGS:CUTR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 10.1%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.9%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:CUTR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:CUTR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 211 7 4 3
2020-12-31 186 1 -5 4
2019-12-31 170 -15 -13 4
NasdaqGS:CUTR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 165 2 -37
2018-12-31 163 0 -31
2018-09-30 165 -1 18
2018-06-30 162 4 25
2018-03-31 156 8 29
2017-12-31 151 14 30
2017-09-30 142 12 11
2017-06-30 134 10 7
2017-03-31 125 2 4
2016-12-31 118 2 3
2016-09-30 110 1 0
2016-06-30 103 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cutera's earnings are expected to grow significantly at over 20% yearly.
  • Cutera's revenue is expected to grow by 10.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:CUTR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Cutera Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:CUTR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.33 0.48 0.17 2.00
2020-12-31 -0.31 -0.12 -0.59 4.00
2019-12-31 -0.85 -0.66 -1.09 4.00
NasdaqGS:CUTR Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.66
2018-12-31 -2.23
2018-09-30 1.34
2018-06-30 1.85
2018-03-31 2.10
2017-12-31 2.16
2017-09-30 0.82
2017-06-30 0.50
2017-03-31 0.27
2016-12-31 0.19
2016-09-30 0.03
2016-06-30 -0.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cutera will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Cutera's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cutera has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CUTR Past Performance

  How has Cutera performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cutera's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cutera does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Cutera's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cutera's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Cutera's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cutera Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:CUTR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 164.62 -36.96 82.52 14.51
2018-12-31 162.72 -30.77 79.42 14.36
2018-09-30 164.88 18.40 77.91 14.38
2018-06-30 162.48 25.46 74.80 14.60
2018-03-31 156.32 28.98 70.70 13.49
2017-12-31 151.49 29.99 66.16 12.87
2017-09-30 141.74 11.33 61.42 12.29
2017-06-30 133.84 6.78 58.19 11.74
2017-03-31 124.93 3.61 56.56 11.47
2016-12-31 118.06 2.58 54.51 11.23
2016-09-30 110.22 0.41 53.02 11.15
2016-06-30 103.03 -2.19 51.46 10.98
2016-03-31 98.11 -2.85 48.83 11.00
2015-12-31 94.76 -4.44 48.07 10.73
2015-09-30 90.22 -8.12 47.75 10.57
2015-06-30 85.86 -9.79 46.72 10.45
2015-03-31 81.02 -10.65 44.93 10.34
2014-12-31 78.14 -10.61 43.45 10.54
2014-09-30 74.88 -9.27 41.63 10.33
2014-06-30 72.98 -8.30 39.64 10.14
2014-03-31 74.82 -6.19 38.87 9.74
2013-12-31 74.59 -4.75 37.92 9.22
2013-09-30 74.89 -3.39 36.54 8.90
2013-06-30 77.49 -2.62 37.34 8.68
2013-03-31 77.52 -3.44 37.79 8.33
2012-12-31 77.28 -6.55 39.41 8.43
2012-09-30 73.29 -8.51 39.52 8.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cutera has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cutera has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cutera improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cutera's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cutera has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CUTR Health

 How is Cutera's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cutera's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cutera is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cutera's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cutera's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Cutera has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cutera Company Filings, last reported 3 months ago.

NasdaqGS:CUTR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 39.12 0.00 27.10
2018-12-31 46.39 0.00 35.58
2018-09-30 70.40 0.00 26.88
2018-06-30 69.37 0.00 29.01
2018-03-31 67.86 0.00 23.97
2017-12-31 64.89 0.00 35.91
2017-09-30 61.21 0.00 50.48
2017-06-30 60.23 0.00 50.95
2017-03-31 59.44 0.00 48.43
2016-12-31 61.01 0.00 54.07
2016-09-30 52.41 0.00 46.38
2016-06-30 48.33 0.00 43.32
2016-03-31 49.59 0.00 44.45
2015-12-31 50.03 0.00 48.41
2015-09-30 49.33 0.00 47.74
2015-06-30 67.69 0.00 66.34
2015-03-31 78.57 0.00 76.06
2014-12-31 80.51 0.00 81.15
2014-09-30 80.71 0.00 80.70
2014-06-30 81.76 0.00 81.60
2014-03-31 83.38 0.00 83.82
2013-12-31 84.27 0.00 83.07
2013-09-30 85.62 0.00 82.28
2013-06-30 93.26 0.00 89.63
2013-03-31 93.15 0.00 88.09
2012-12-31 90.77 0.00 85.57
2012-09-30 87.77 0.00 80.13
  • Cutera has no debt.
  • Cutera has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Cutera has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Cutera has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by % per year.
X
Financial health checks
We assess Cutera's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cutera has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CUTR Dividends

 What is Cutera's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cutera dividends.
If you bought $2,000 of Cutera shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cutera's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cutera's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:CUTR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:CUTR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cutera has not reported any payouts.
  • Unable to verify if Cutera's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cutera's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cutera has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cutera's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cutera afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cutera has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CUTR Management

 What is the CEO of Cutera's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dave Mowry
AGE 57
TENURE AS CEO 0 years
CEO Bio

Mr. David H. Mowry, also known as Dave, is the Chief Executive Officer and Director at Cutera, Inc. since July 9, 2019. Mr. Mowry served as the Director, President and Chief Executive Officer of Vyaire Medical since May 2016. He has more than 27 years of medical device industry experience in the medical device industry including the areas of manufacturing, logistics, quality assurance and general management. While serving at Vyaire, Mr. Mowry led the efforts to carve-out four separate divisions from Becton-Dickinson and Company (BDX), following its acquisition of CareFusion, combining the units into a standalone, singularly-focused Respiratory Care company. He served as the Chief Operating Officer, Executive Vice President and Executive Director of Wright Medical Group N.V. since October 10, 2015 until May 6, 2016. Prior to Vyaire, he served as the Chief Executive Officer and President of Tornier N.V. (Tornier Inc) from February 12, 2013 to October 1, 2015. He served as the Interim Chief Executive Officer and Interim President of Tornier N.V. since November 2012 and its Chief Operating Officer from July 20, 2011 to November 2012 and Executive Vice President since October 1, 2015. He served as the President of Covidien plc's Global Neurovascular Division from July 2010 to July 2011. He served as a Senior Vice President and President of Worldwide Neurovascular of ev3 Inc. from January 2010 to July 2010 and also served as its Senior Vice President of Worldwide Operations from August 2007 to January 2010 and Senior Vice President of Strategy, Corporate Manufacturing and Corporate Operations from July 2008 to December 2009. He served as Vice President of Operations for ev3 Neurovascular from November 2006 to October 2007. Mr. Mowry served as a Vice President of Operations and Logistics at the ZimmerSpine division of Zimmer Holdings from February 2002 to November 2006, Inc. He served as the President and Chief Operating Officer of HeartStent Corp. from February 2002 to November 2006. He has been Independent Director of Alphatec Holdings, Inc. (alternative name Alphatec Spine, Inc.) since February 8, 2017. He served as a Director of EndoChoice Holdings, Inc. from September 9, 2015 to November 22, 2016. He served as a member of the board of directors of Tornier N.V. from February 2013 to October 2015. Prior to Tornier, Mr. Mowry served as President of Covidien’s Neurovascular Division, a recognized leader in the hemorrhagic and ischemic stroke interventional device markets. Mr. Mowry holds a BS of the United States Military Academy in West Point, New York with a degree in Engineering and Mathematics.

CEO Compensation
  • Insufficient data for Dave to compare compensation growth.
  • Insufficient data for Dave to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Cutera management team in years:

1.6
Average Tenure
53
Average Age
  • The average tenure for the Cutera management team is less than 2 years, this suggests a new team.
Management Team

R. Richey

TITLE
President & COO
COMPENSATION
$3M
AGE
45
TENURE
0.3 yrs

Sandy Gardiner

TITLE
Executive VP & CFO
COMPENSATION
$639K
AGE
53
TENURE
1.6 yrs

Dave Mowry

TITLE
CEO & Director
AGE
57

Michael Karavitis

TITLE
Executive VP & Chief Technology Officer
TENURE
1.9 yrs

Matthew Scalo

TITLE
Vice President of Investor Relations & Corporate Development

Darren Alch

TITLE
VP, General Counsel & Secretary
AGE
53

Marina Kamenakis

TITLE
Senior Vice President of Global Marketing & Clinical Development
AGE
60
TENURE
1.4 yrs

Cindee Van Vleck

TITLE
Head of Human Officer
TENURE
1.4 yrs

Larry Laber

TITLE
Executive Vice President of Sales - North America
COMPENSATION
$2M
AGE
48
TENURE
4.8 yrs

Ron Santilli

TITLE
Executive Officer
COMPENSATION
$984K
AGE
59
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the Cutera board of directors in years:

5.3
Average Tenure
64
Average Age
  • The tenure for the Cutera board of directors is about average.
Board of Directors

Dan Plants

TITLE
Chairman
COMPENSATION
$201K
AGE
52
TENURE
2.8 yrs

Dave Mowry

TITLE
CEO & Director
AGE
57

Tim O'Shea

TITLE
Independent Director
COMPENSATION
$161K
AGE
66
TENURE
15.3 yrs

Greg Barrett

TITLE
Non-Executive Director
COMPENSATION
$174K
AGE
65
TENURE
7.8 yrs

Kay Napier Zanotti

TITLE
Independent Director
AGE
64
TENURE
0.4 yrs

Joe Whitters

TITLE
Independent Director
AGE
60
TENURE
0.4 yrs

David Apfelberg

TITLE
Independent Director
COMPENSATION
$151K
AGE
77
TENURE
20.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
04. Jun 19 Buy Voce Capital Management, LLC Company 31. May 19 03. Jun 19 28,166 $16.93 $471,137
16. May 19 Buy Voce Capital Management, LLC Company 14. May 19 14. May 19 7,145 $16.95 $121,113
25. Jan 19 Buy Teton Advisors, Inc Company 17. Dec 18 19. Dec 18 1,000 $15.73 $15,711
25. Jan 19 Sell GAMCO Investors, Inc. Company 30. Nov 18 24. Jan 19 -25,100 $17.02 $-6,578
25. Jan 19 Buy GAMCO Investors, Inc. Company 10. Dec 18 22. Jan 19 161,801 $17.94 $542,428
30. Nov 18 Sell GAMCO Investors, Inc. Company 08. Nov 18 26. Nov 18 -4,100 $21.76 $-4,352
30. Nov 18 Buy GAMCO Investors, Inc. Company 01. Nov 18 29. Nov 18 153,327 $21.65 $787,796
01. Nov 18 Buy Teton Advisors, Inc Company 10. Oct 18 18. Oct 18 6,000 $23.08 $135,699
01. Nov 18 Sell GAMCO Investors, Inc. Company 10. Oct 18 26. Oct 18 -9,500 $23.12 $-11,561
01. Nov 18 Buy GAMCO Investors, Inc. Company 08. Oct 18 31. Oct 18 144,180 $23.26 $556,508
09. Oct 18 Buy Teton Advisors, Inc Company 12. Sep 18 03. Oct 18 12,700 $32.00 $392,351
09. Oct 18 Buy GAMCO Investors, Inc. Company 29. Aug 18 05. Oct 18 165,300 $34.10 $4,320,333
30. Aug 18 Buy James Reinstein Individual 29. Aug 18 29. Aug 18 1,000 $32.02 $32,016
23. Aug 18 Buy Teton Advisors, Inc Company 08. Aug 18 09. Aug 18 21,143 $34.41 $713,610
23. Aug 18 Buy GAMCO Investors, Inc. Company 06. Jul 18 22. Aug 18 122,900 $43.44 $4,265,982
X
Management checks
We assess Cutera's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cutera has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CUTR News

Simply Wall St News

Announcing: Cutera (NASDAQ:CUTR) Stock Increased An Energizing 107% In The Last Five Years

View our latest analysis for Cutera Because Cutera is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. … In the last 5 years Cutera saw its revenue grow at 19% per year.

Simply Wall St -

Estimating The Intrinsic Value Of Cutera, Inc. (NASDAQ:CUTR)

Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value: 10-year free cash flow (FCF) forecast 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF ($, Millions) $-15.57 $-0.49 $6.57 $9.51 $12.56 $15.50 $18.15 $20.48 $22.49 $24.21 Growth Rate Estimate Source Analyst x1 Analyst x1 Analyst x1 Est @ 44.76% Est @ 32.15% Est @ 23.32% Est @ 17.15% Est @ 12.82% Est @ 9.79% Est @ 7.67% Present Value ($, Millions) Discounted @ 8.39% $-14.37 $-0.41 $5.16 $6.89 $8.40 $9.56 $10.33 $10.75 $10.89 $10.82 Present Value of 10-year Cash Flow (PVCF)= $58.03m "Est" = FCF growth rate estimated by Simply Wall St After calculating the present value of future cash flows in the intial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. … In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 8.4%. … Terminal Value (TV) = FCF2029 × (1 + g) ÷ (r – g) = US$24m × (1 + 2.7%) ÷ (8.4% – 2.7%) = US$440m Present Value of Terminal Value (PVTV) = TV / (1 + r)10 = $US$440m ÷ ( 1 + 8.4%)10 = $196.60m The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is $254.62m.

Simply Wall St -

Did Cutera, Inc. (NASDAQ:CUTR) Insiders Sell Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So we'll take a look at whether insiders have been buying or selling shares in Cutera, Inc. … But logic dictates you should pay some attention to whether insiders are buying or selling shares.

Simply Wall St -

Estimating The Fair Value Of Cutera, Inc. (NASDAQ:CUTR)

by taking the expected future cash flows and discounting them to their present value. … Discounted Cash Flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

Does Cutera, Inc. (NASDAQ:CUTR) Have A Good P/E Ratio?

To keep it practical, we'll show how Cutera, Inc.'s (NASDAQ:CUTR) P/E ratio could help you assess the value on offer. … Cutera has a price to earnings ratio of 11.61, based on the last twelve months. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

How Does Cutera, Inc. (NASDAQ:CUTR) Affect Your Portfolio Volatility?

Volatility is considered to be a measure of risk in modern finance theory. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider.

Simply Wall St -

Is Cutera Inc (NASDAQ:CUTR) A Financially Sound Company?

However, the trade-off is CUTR will have to adhere to stricter debt covenants and have less financial flexibility. … Is financial flexibility worth the lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Is There Now An Opportunity In Cutera Inc (NASDAQ:CUTR)?

received a lot of attention from a substantial price movement on the NasdaqGS over the last few months, increasing to $40.95 at one point, and dropping to the lows of $19.91. … A question to answer is whether Cutera's current trading price of $20.48 reflective of the actual value of the? … Let’s take a look at Cutera’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change

Simply Wall St -

Boasting A 37% Return On Equity, Is Cutera Inc (NASDAQ:CUTR) A Top Quality Stock?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … That means that for every $1 worth of shareholders' equity, it generated $0.37 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Calculating The Intrinsic Value Of Cutera Inc (NASDAQ:CUTR)

by estimating the company's future cash flows and discounting them to their present value. … discounted cash flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

CUTR Company Info

Description

Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. It also provides excel V, a vascular and benign pigmented lesion treatment platform; xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; Juliet, a laser system for vaginal health; and Secret RF, a fractional radio frequency microneedling device for skin revitalization. In addition, the company offers GenesisPlus, CoolGlide, myQ, enlighten SR, and truSculpt iD products. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills and marketing brochures through the Internet. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, physicians performing aesthetic treatments in non-medical offices, and other qualified practitioners, as well as for physicians offering aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1998 and is headquartered in Brisbane, California.

Details
Name: Cutera, Inc.
CUTR
Exchange: NasdaqGS
Founded: 1998
$351,205,039
14,036,972
Website: http://www.cutera.com
Address: Cutera, Inc.
3240 Bayshore Boulevard,
Brisbane,
California, 94005,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CUTR Common Stock Nasdaq Global Select US USD 31. Mar 2004
DB TJ9 Common Stock Deutsche Boerse AG DE EUR 31. Mar 2004
Number of employees
Current staff
Staff numbers
402
Cutera employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/16 23:55
End of day share price update: 2019/07/16 00:00
Last estimates confirmation: 2019/07/09
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.